Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Innovation Council · Finished

ECLIPSE ECL-based Infectious Pathogen (bio)SEnsor

Coordinator
Alma Mater Studiorum - Universita Di Bologna, Italy
Runs
1 May 2022 to 31 October 2025
Status
Finished
EU funding
€2.7m
Total cost
€2.7m
Partners
10 organisations in 4 countries
Type
European Innovation Council
Grant agreement
101046787

What the project is doing

In the project's own words, from its summary on CORDIS.

Infectious diseases are a threat to mankind since their appearance in human history. Despite the advances in science and technologies, such threats are still recurrent, as recently shown by the COVID-19 pandemic in 2020 – 2021, which has revealed the urgent need for novel tools for pathogen detection that would be at the same time reliable, fast, cheap, portable and simple. The goal of ECLIPSE is to address this need, with a new platform exploiting innovative ultrasensitive protocols for the detection of pathogens.

ECLIPSE builds on the combination of interdisciplinary elements to facilitate the transfer to industry, i.e., (i) ElectroChemiLuminescence (ECL) as a very sensitive transduction mechanism for realizing simple, portable and cheap devices, (ii) bio-, nano-, and supramolecular-based signal amplification structures for increasing the sensitivity, and (iii) two recognition strategies to afford high affinity and selectivity, thus leading to high reliability: the Phage-Sandwich technology for the whole pathogen, and the Surface Cooperative Hybridization technology for microbial and viral nucleic acid.

We will demonstrate the feasibility and adaptability of the ECLIPSE platform with three test cases: a virus (SARS-CoV-2), a bacterium (Pseudomonas aeruginosa) and a protozoan parasite (Leishmania infantum). The platform is designed to be applied to many other infectious agents, making it a ""ready for the next pandemic” technology. ECLIPSE is expected to become a game-changer in European countries, where it could be a cornerstone for fast testing and reliable tracking of infections, and in developing countries that will benefit from a cheap and simple approach to detect the many infectious diseases that affect millions of people every year.

The project results will be validated and demonstrated at partners’ premisses.""

Topics

Who is involved

OrganisationCityCountryRole
Alma Mater Studiorum - Universita Di BolognaBolognaItalyCoordinator
MetaSint-Joost-Ten-NodeBelgiumParticipant
Csem Centre Suisse D'electronique Et De Microtechnique SA - Recherche Et DeveloppementNeuchatelSwitzerlandAssociatedpartner
Karlsruher Institut Fuer TechnologieKarlsruheGermanyParticipant
Irccs Azienda Ospedaliero- Universitaria Di BolognaBolognaItalyThird party
Istituto Di Ricerche Farmacologiche Mario NegriMilanoItalyParticipant
Meta Group SRLRomaItalyThird party
Personal Genomics SRLVeronaItalyParticipant
Universita Degli Studi Di MessinaMessinaItalyParticipant
Universita Degli Studi Di MilanoMilanoItalyThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI